
Forest Laboratories will spend around $2.9 billion to purchase Aptalis, a privately-held US firm specialising in treatments for gastrointestinal disorders …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

